Geron Corp (GERN) stock
GERNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.00+0.06 (+6.17%)
Close on Nov 17, 2026Market cap $642.47MP/E –Yield –
Geron ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Geron's ebitda for the twelve months ending Jun 30, 2026 was -$51.28M. For fiscal 2025 it was -$68.11M. The highest annual figure on record is -$68.11M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$68.11M | – |
| FY2024 | Dec 31, 2024 | -$173.19M | – |
| FY2023 | Dec 31, 2023 | -$193.50M | – |
| FY2022 | Dec 31, 2022 | -$138.26M | – |
| FY2021 | Dec 31, 2021 | -$113.78M | – |
| FY2020 | Dec 31, 2020 | -$76.76M | – |
| FY2019 | Dec 31, 2019 | -$72.44M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$12.36M | – |
| Q1 FY2026 | Mar 31, 2026 | $292.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$25.45M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.76M | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.33M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.57M | – |
| Q4 FY2024 | Dec 31, 2024 | -$19.91M | – |
| Q3 FY2024 | Sep 30, 2024 | -$28.18M | – |
| Q2 FY2024 | Jun 30, 2024 | -$69.07M | – |
| Q1 FY2024 | Mar 31, 2024 | -$56.02M | – |
| Q4 FY2023 | Dec 31, 2023 | -$54.18M | – |
| Q3 FY2023 | Sep 30, 2023 | -$47.50M | – |
| Q2 FY2023 | Jun 30, 2023 | -$51.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$39.99M | – |
| Q4 FY2022 | Dec 31, 2022 | -$41.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$39.87M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.90M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.62M | – |
| Q4 FY2021 | Dec 31, 2021 | -$30.92M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.62M | – |
| Q2 FY2021 | Jun 30, 2021 | -$28.84M | – |
| Q1 FY2021 | Mar 31, 2021 | -$28.41M | – |
| Q4 FY2020 | Dec 31, 2020 | -$23.22M | – |
See a number that looks wrong?